KalVista Pharmaceuticals, Inc. KALV
27.00 USD 0.00 (+0.00%)
At closeJun 10, 2026, 4:00 PM EDT
26.99 -0.01 -0.04%
After hours · Jun 10, 4:00 PM ET
26.98 Day range 27.00
10.41 52-week range 27.00
- YTD
- +67.18%
- 1 year
- +106.26%
- Market cap
- 1.44B
- Revenue (ttm)
- 114.48M
- Profit margin
- -118.74%
- Shares out
- 53.24M
- Forward P/E
- 15.82
- YTD return
- +67.18%
- 1-year return
- +106.26%
- Volume
- 4.26M
- Avg volume
- 3.07M
- Open
- 26.99
- Previous close
- 27.00
- Day's range
- 26.98 – 27.00
- 52-week range
- 10.41 – 27.00
- Beta
- -0.11
- Analysts
- Hold
- Price target
- 27.00 (+0.0%)
- Earnings date
- Dec 3, 2026
2Y 0.00 (0.00%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 1.44B
- PEG ratio
- 0.00
- Price / sales
- 12.56
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 285.03M
- Total debt
- 284.31M
- Return on equity
- 0.00%
- Short % of float
- 14.37%
- 50-day average
- 24.43
- 200-day average
- 17.09
Analyst view
Consensus: hold
Hold
Price target (mean) 27.00
Ratings (0m) 5 0 buy · 5 hold · 0 sell
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Dec 3, 2026
Expected Dec 3, 2026. Consensus EPS estimate -0.28667.
Financials — quick view
KALV Revenue — quarterly 40.86M
KALV Net income — quarterly -23.49M
KALV EPS — quarterly -0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 3, 2026 | Oct 30, 2026 | -0.29429 | — | — | — |
| Aug 13, 2026 | Jul 30, 2026 | -0.28667 | — | — | — |
| May 15, 2026 | Dec 31, 2025 | -0.41714 | -1.08 | -0.66 | -158.91% |
| Mar 25, 2026 | Mar 31, 2026 | -0.54 | -0.425 | +0.12 | +21.30% |
| Nov 10, 2025 | Sep 30, 2025 | -0.96 | -0.92 | +0.04 | +4.17% |
| Sep 11, 2025 | Jul 31, 2025 | -0.91 | -1.12 | -0.21 | -23.08% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 30, 2026 | Needham | down | Buy | Hold |
| Mar 26, 2026 | Stifel | main | Buy | Buy |
| Mar 26, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Mar 25, 2026 | Needham | main | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About KalVista Pharmaceuticals, Inc.
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kalvista.com
News
Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings 
General Dynamics, Visa, NXP Semiconductors, Penske Automotive And Other Big Stocks Moving Higher On Wednesday - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
9 Health Care Stocks With Whale Alerts In Today's Session 
Earnings Scheduled For March 25, 2026 
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - 12 Health Care Stocks Moving In Friday's Pre-Market Session
Greenbrier, General Motors And 3 Stocks To Watch Heading Into Friday
Your note
Sign in to keep a note on KALV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUDHYA PAUL K | Officer | Sale | May 25, 2026 | 150,260 |
| PALLEIKO BENJAMIN L | Chief Executive Officer | Sale | May 21, 2026 | 479,989 |
| PIEKOS BRIAN | Chief Financial Officer | Sale | May 21, 2026 | 21,661 |
| SWEENY NICOLE | Officer | Sale | May 25, 2026 | 59,291 |
| VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 25, 2026 | 0 |
| YEA CHRISTOPHER M | Officer | Sale | May 26, 2026 | 229,918 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Venrock Adviser, LLC | 12.16% | 6,474,485 | 174.81M | Mar 30, 2026 |
| Frazier Life Sciences Management, L.P. | 9.32% | 4,961,108 | 133.95M | Mar 30, 2026 |
| Suvretta Capital Management, LLC | 8.96% | 4,768,712 | 128.76M | Mar 30, 2026 |
| Tang Capital Management, LLC | 8.59% | 4,573,530 | 123.49M | Mar 30, 2026 |
| Blackrock Inc. | 7.13% | 3,795,897 | 102.49M | Mar 30, 2026 |
| SilverArc Capital Management, LLC | 5.40% | 2,876,407 | 77.66M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 5.28% | 2,808,583 | 75.83M | Mar 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.54% | 1,349,851 | 36.45M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.26% | 1,204,868 | 32.53M | Apr 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.70% | 905,839 | 24.46M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.83% | 439,451 | 11.87M | Mar 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.71% | 375,708 | 10.14M | Feb 27, 2026 |